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1 |  INTRODUCTION
Sleeping sickness, transmitted by the tsetse fly, is caused by 
two subspecies of the protozoan parasite Trypanosoma bru-
cei: T. b. gambiense typically establishes a chronic infection, 
whereas T. b. rhodesiense causes a rather acute form of the 
disease. A third subspecies, T. b. brucei, is not infective to 
humans but, together with other trypanosome species, causes 
livestock trypanosomiasis. Trypanosomes are protected from 
the mammalian immune system by multiple mechanisms 
that confound both innate and acquired defenses. The sur-
face coat consists of a dense layer of a single variant surface 
glycoprotein (VSG); with a reservoir of more than 2000 VSG 
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Abstract
Suramin was introduced into the clinic a century ago and is still used to treat the first 
stage of acute human sleeping sickness. Due to its size and sixfold negative charge, 
uptake is mediated through endocytosis and the suramin receptor in trypanosomes 
is thought to be the invariant surface glycoprotein 75 (ISG75). Nevertheless, we re-
cently identified a variant surface glycoprotein (VSGSur) that confers strong in vitro 
resistance to suramin in a Trypanosoma brucei rhodesiense line. In this study, we 
introduced VSGSur into the active bloodstream expression site of a T. b. brucei line. 
This caused suramin resistance and cross resistance to trypan blue. We quantified the 
endocytosis of different substrates by flow cytometry and showed that the expression 
of VSGSur strongly impairs the uptake of low‐density lipoprotein (LDL) and transfer-
rin, both imported by receptor‐mediated endocytosis. However, bulk endocytosis and 
endocytosis of the trypanolytic factor were not affected, and the VSGSur‐expressors 
did not exhibit a growth phenotype in the absence of suramin. Knockdown of ISG75 
was synergistic with VSGSur expression, indicating that these two proteins are me-
diating distinct suramin resistance pathways. In conclusion, VSGSur causes suramin 
resistance in T. brucei bloodstream forms by decreasing specific, receptor‐mediated 
endocytosis pathways.
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genes and pseudogenes,1 trypanosomes evade their mamma-
lian host's adaptive immune responses by antigenic variation. 
Thus there is no vaccine for sleeping sickness and chemo-
therapy relies on few available drugs, although more are en-
tering the treatment pipeline.2 Suramin is the oldest drug but 
remains used for the treatment of the first stage of T. b. rhod-
esiense infection.
Despite the use of suramin for a hundred years, its mode 
of action against African trypanosomes is not completely 
understood. Suramin inhibits a number of different enzymes 
including many in the glycolytic pathway.3 As a negatively 
charged molecule, suramin cannot cross membranes by dif-
fusion and was proposed to be taken up through receptor‐me-
diated endocytosis.4,5 More recent RNAi target sequencing 
studies showed that knock‐down of a number of endosomal 
and lysosomal genes leads to up to about 11‐fold suramin re-
sistance,6 substantiating an uptake route through endocytosis. 
Invariant surface glycoprotein 75 (ISG75) was proposed to 
act as the suramin receptor, since its knock‐down led to a de-
crease in suramin sensitivity.6 Suramin shows a high plasma 
protein binding with approximately 70% bound to albumin, 
15% to low‐density lipoprotein (LDL) and 15% free.5 Based 
on findings that trypanosomes took up >20‐fold more sura-
min in the presence of LDL than in the presence of plasma, 
whereas the binding and uptake of LDL were up to 70% re-
duced in the presence of high micromolar concentrations of 
suramin,5 suramin was proposed to be taken up in complex 
with LDL. However, procyclic trypanosomes overexpressing 
the trypanosome ortholog of Rab4 showed a 50% decrease in 
suramin binding and almost no suramin uptake when com-
pared with parental cells, whereas the uptake of LDL was 
unchanged.7 The expression of a constitutively activated ver-
sion of Rab5 led to increased LDL uptake without affecting 
suramin uptake, indicating that uptake of LDL and suramin 
are likely independent.7
While resistance to suramin is widespread in the animal 
pathogen Trypanosoma evansi with 50% inhibitory concen-
trations (IC50) of up to 40 µg/mL,8,9 there have not been any 
reports of suramin resistance in T. brucei spp. from the field. 
Nevertheless, resistance can be selected for under in vitro and 
in vivo conditions in the laboratory.10 We recently described 
a variant surface glycoprotein, VSGSur, which is linked to sur-
amin resistance.11 VSGSur was identified by forward genetics. 
We had exposed T. b.  rhodesiense STIB900 clones to high 
suramin concentrations (80‐fold the IC50), and within only 
one week they became resistant. Transcriptome sequencing 
showed that all the resistant lines had switched to express 
VSGSur. This phenomenon was reproducible in multiple in-
dependent experiments. The VSGSur expressing parasites 
showed an increase in IC50 of almost 100‐fold for suramin, 
and cross resistance to trypan blue, a trypanocidal dye related 
to suramin. We quantified the amount of intracellular trypan 
blue and observed a reduced uptake by VSGSur expressing 
parasites.11 In this study, we investigate the effects of en-
forced VSGSur expression in a suramin‐sensitive T. b. brucei 
line, aiming to uncover the molecular mechanisms underlying 
the link between VSGSur expression and suramin resistance.
2 |  MATERIALS AND METHODS
Chemicals were purchased from Merck KGaA, Darmstadt, 
Germany, if not otherwise stated.
2.1 | T. brucei strains and cell culture
The Lister 427 derived T. b. brucei 2T1 strain12 was culti-
vated in Iscove's Modified Dulbecco's culture Medium com-
plemented according to Hirumi13 and supplemented with 
10% heat‐inactivated fetal calf serum. Cells were cultured at 
37°C, 5% CO2.
2.2 | Introduction of VSGSur into 2T1 cells
The plasmid previously described11 was modified for the 
genomic replacement of the VSG221 by VSGSur in 2T1 cells. 
First the coding sequence of VSG900 within the plasmid was 
replaced by the coding sequence of VSGSur (GenBank acces-
sion MF093647), which was derived by PCR from cDNA of 
STIB900_c1_sur1 with primers containing XbaI and AscI re-
striction sites (VSGsur_XbaI_F: taatctagaatgcaagccgtaacacgc, 
VSGsur_AscI_R: aatggcgcgccttaaaaaagcaaaaatgcaagc). The 
construct's framing UTRs used for homologous recombina-
tion were replaced with the UTR‐regions of VSG221. For the 5′ 
genomic UTR of VSG221 a PCR product amplified from 2T1 
gDNA was cloned into the plasmid. Primer used for the ampli-
fication of the 5′ genomic UTR of VSG221 contained HindIII 
and NcoI sites (VSG221_5′UTR_HindIII_f: tagaagcttcaa-
gcacaatttcatcctcct and VSG221_5′UTR_NcoI_r: catccatgggc-
cgcgttcgtgtcg). Correct cloning was validated by sequencing. 
The 3′ UTR was replaced during the final PCR on plasmid 
DNA using a forward primer, which binds to the 221 5′UTR 
sequence (VSG221_5′UTR_HindIII_f), and a reverse primer, 
which binds to the stop‐codon of VSGSur and contains an over-
hang of 71 nucleotides from the VSG221 3′UTR sequence. The 
resulting PCR product was framed by the 3′ and 5′ UTRs of 
VSG221 and contained a blasticidine‐resistance gene, an αβ tu-
bulin trans‐splice site and the coding sequence of VSGSur. Five 
micrograms of the purified PCR product were used for the trans-
fection of 4 × 107 2T1 cells in 100 µL Tb‐BSF buffer14 with an 
Amaxa Nucleofector using program Z‐001. Positive‐transfected 
clones were obtained by limiting dilution in standard culture me-
dium and after 24 hours of incubation, blasticidine was added to 
a total concentration of 10 and 20 µg/mL. Four positive‐trans-
fected clones and the untransfected parent strain were analyzed 
by qPCR regarding the expression of VSGSur and VSG221.
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2.3 | RNA isolation and quantitative PCR
Parasites in the exponential growth phase were washed once 
with PBS and total RNA was isolated using the RNeasy 
Mini Kit (Qiagen) including an on‐column DNase treat-
ment. SuperScript  III Reverse Transcriptase (Invitrogen 
via Thermo Fisher Scientific) and an oligo(dT) primer 
were used to synthesize complementary DNA (cDNA) 
out of 1‐5  µg total RNA according to the manufacturer's 
protocol. Quantitative PCR was carried out in a Power 
SYBR Green Mix (Applied Biosystems via Thermo Fisher 
Scientific) on a StepOnePlus real‐time PCR machine 
(Applied Biosystems) in technical duplicates. The primers 
used for qPCR were tcattcgtttggccatacgc and ttactgacagac-
gaaccggc for VSGSur and aaggccaagaaagcg and ttggtaacgc-
ctgttttg for VSG221. The amplification plots were analyzed 
with StepOne Software v2.3. and the Ct values were nor-
malized to the housekeeping gene telomerase reverse tran-
scriptase using the ∆∆Ct method.
2.4 | Drug and human serum 
sensitivity assays
Suramin (sodium salt) (S2671) and pentamidine isethion-
ate (P0547) were obtained from Sigma (now Merck), 
trypan blue (93590) from Fluka (now Merck) and melarso-
prol from Sanofi‐Aventis/WHO. In vitro drug sensitivities 
were determined with Alamar blue assays15 using standard 
growth medium. Serial drug dilutions were prepared on a 
96‐well plate and parasites were added to a final concen-
tration of 1 × 104 cells/mL. After incubation for 69 hours, 
resazurin was added to a final concentration of 11.4 µg/mL. 
Cells were incubated for 2‐4 more hours and fluorescence 
of viable cells was quantified using a SpectraMax reader 
(Molecular Devices) and SoftMax Pro 5.4.5 Software. 
Dose‐response curves were fitted with a nonlinear regres-
sion model (variable slope; four parameters, lowest value 
set to zero) and IC50 values were calculated with GraphPad 
Prism 6.00. Human serum sensitivity was determined using 
Alamar blue assays as above. But, instead of drug addition, 
limited dilutions were prepared with human serum and the 
medium used was HMI‐9 supplemented with 15% heat‐
inactivated horse serum (i‐horse). Human serum was ob-
tained through centrifugation of whole blood of volunteers, 
heat inactivated at 56°C and stored at −20°C. Specific kill-
ing due to trypanolytic factor was checked by incubation 
of T. b. gambiense in 5% human serum of the same batch. 
T. b. gambiense cells were not lysed.
2.5 | Trypan blue uptake
Cells were harvested in the logarithmic growth phase and 
resuspended in standard growth medium at a concentration 
of 4 × 105 cells/mL. Trypan blue was added to the respec-
tive concentrations and cells incubated for 2 hours at 37°C. 
Subsequently, cells were centrifuged for 5 minutes at 3000 g 
at room temperature and washed twice with PBS. Cells 
were resuspended in 250 µL PBS and fixed in 5% formalin. 
Fluorescence intensities of the cells were measured with a BD 
FACSCalibur™ flow cytometer (BD Biosciences). A total 
of 10 000 events were acquired within a gate of intact cells 
based on size versus granularity (FSC/SSC) and fluorescence 
of the gated cells was measured in the FL3 filter. The meas-
ured fluorescence intensities were analyzed with Flowing 
Software (version 2.5.1) using a refined FSCxSSC gate to 
exclude cell debris and an additional size versus fluorescence 
gate to exclude parasites that had already been dead during 
incubation with trypan blue and thus gave a much stronger 
signal. Fluorescence values were defined as the geometrical 
mean fluorescence of gated particles (>6000 per replicate).
2.6 | ISG75 turnover
For each cell line and each timepoint, 40  mL cell cultures 
were prepared the day before the experiment. The cell den-
sity was adjusted for each sample to reach 1.2 × 10 cells/mL. 
The next day, at the respective time points, cycloheximide 
(C7698 Sigma, now Merck) was added to the cultures to a 
concentration of 100 µg/mL. At timepoint zero, the cell den-
sities were measured and the same number of cells was taken 
from each replicate. Cells were centrifuged for 10 minutes, 
1000 g at room temperature. The supernatant was removed 
and the cell pellet resuspended in 1 mL PBS supplemented 
with protease inhibitor (cOmplete™, Mini, EDTA‐free 
Protease Inhibitor Cocktail, Roche: 1 tab in 20ml) and centri-
fuged for 10 minutes, 1000 g at room temperature. The cells 
were washed one more time with PBS containing protease in-
hibitor, supernatant was removed and 10 µL of 3 × Laemmli 
buffer added. Cells were further diluted with Laemmli buffer 
to reach a density of 5 × 106 cells/ 10 µl. Cells were soni-
cated and incubated at 70°C for 10 minutes. Samples were 
centrifuged at full speed in a microcentrifuge for 2 minutes 
and subsequently 10 µL of sample was loaded on a NuPAGE 
4%‐12% Bis‐Tris Protein Gel (Fisher Scientific ‐ UK Ltd) 
and run for 1  hour at 200  V in NuPAGE™ MOPS SDS 
Running Buffer (Fisher Scientific ‐ UK Ltd). Separated pro-
teins were transferred to a polyvinylidene difluoride (PVDF) 
membrane (Immobilon‐P; Millipore) in a TE22 wet trans-
fer tank (GE healthcare) in SDS‐Page running buffer sup-
plemented with 20% methanol. The membrane was blocked 
with blocking buffer consisting of Tris‐buffered saline with 
0.01% Tween‐20 (TBST) and 5% milk powder. Subsequently 
the membrane was incubated for 1 hour in blocking buffer 
containing the primary antibody. For ISG75 a 1:2,500 di-
luted polyclonal rabbit antibody was used and for EF1α a 
monoclonal mouse antibody (clone CBP‐KK1; Millipore) 
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was used in a 1:20  000 dilution. Membranes were washed 
with TBST three times for 5 minutes and incubated for one 
hour with a secondary goat anti‐rabbit peroxidase‐conju-
gated IgG (A0545, Sigma, now Merck) at a 1:20 000 dilu-
tion. Membranes were washed once with TBS and twice with 
PBS before the addition of 1 mL Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare Life Sciences). 
After two minutes of incubation, chemiluminescence was de-
tected with a G:box imager (Syngene). Signals were quanti-
fied using ImageJ (Fiji) software.16
2.7 | ISG75 knock‐down
A previously described pRPa plasmid for RNAi‐mediated 
knockdown of ISG756 was amplified in DH5α cells and di-
gested with XhoI. A total of 6 µg purified digested plasmid 
was used to transfect 4 × 107 VSG221, respectively, VSGSur 
expressing 2T1 cells. Transfection was carried out as de-
scribed above and positive transfectants were selected with 
10  µg/mL Hygromycin (Invivogen). Pseudoclones were 
picked after five days and RNAi‐knockdown was induced by 
the addition of 1 µg/mL Tetracycline. To quantify the level 
of ISG75 knock‐down, 72 hours after induction, RNA of in-
duced and non‐induced clones was isolated and qPCR was 
performed as described above11 (Wiedemar et al, 2018).11 
Primers used for qPCR were ISG75qPCR_F (gcttgggttgcttgt-
gttct) and ISG75qPCR_R (tcgtatttttgcttttagcattagc).
2.8 | Suramin wash‐out assay
Serial drug dilutions were prepared on a 96‐well v‐shaped 
plate with the following media: HMI‐9 with 15% inacti-
vated horse serum, HMI‐9 without serum, HMI‐9 without 
serum but complemented with 10 µg/mL LDL and HMI‐9 
without serum but complemented with 0.5% bovine serum 
albumin (BSA, A7030). Parasites were washed twice with 
pre‐warmed IMDM, eluted in the respective media and 
added to the assay plates to a final volume of 100 µL/well 
and a concentration of 1 × 105 cells/mL for the HMI‐9 me-
dium with 15% inactivated horse serum. Since the cells 
in the media without serum were not dividing during the 
incubation time, higher inocula were used and parasites 
were added to a concentration of 2 × 105 cells/mL. Plates 
were incubated for 4  hours at 37°C, 5% CO2 and subse-
quently centrifuged at 1000 g for 3 minutes. 50 µL of the 
supernatant was removed and 150 µL pre‐warmed IMDM 
was added to all the wells. Cells were washed three more 
times, each time 150  µL supernatant was removed and 
150 µL IMDM or, in case of the last wash, 150 µL HMI‐9 
with 15% i‐horse was added. After the last centrifugation 
150 µL supernatant was removed and 50 µL HMI‐9 with 
15% i‐horse was added to elute the parasites. A new flat‐
bottom plate was prepared with 50  µL HMI‐9 with 15% 
i‐horse and 50 μL of the eluted parasites were transferred 
to the new plate. The flat‐bottom plate was incubated for 
another 64  hours before resazurin was added to a final 
concentration of 11.4  µg/mL. After another 4‐5  hours of 
incubation at 37°C, 5% CO2, fluorescence of viable cells 
was measured with a SpectraMax (Molecular Devices) and 
SoftMax Pro 5.4.5 Software. Dose‐response curves were 
fitted with a nonlinear regression model (variable slope; 
four parameters, lowest value set to zero) and IC50 values 
were calculated with GraphPad Prism 6.00.
2.9 | Uptake and binding of transferrin and 
low‐density lipoprotein
To quantify the uptake of transferrin and LDL, cells in the 
logarithmic growth phase were washed once with serum‐free 
medium supplemented with 1% BSA and resuspended in 
serum‐free medium supplemented with 1% BSA at a concen-
tration of 2 × 106 cells/mL. 392 µL (for the transferrin uptake 
experiment) and 95 µL (for the LDL uptake experiment) of 
resuspended parasites were transferred to Eppendorf tubes. 
Cells were pre‐incubated for 15 minutes at 37°C to internal-
ize surface bound transferrin and LDL. At the respective 
timepoints fluorescently labeled transferrin (Alexa Fluor™ 
488 Conjugate, T13342, Fisher Scientific, Illkirch Cedex, 
France) was added to a concentration of 50 µg/mL or fluo-
rescently labeled LDL (Bodipy FL, I34359, Fisher Scientific, 
Illkirch Cedex, France) to a concentration of 10 µg/mL. At 
time point zero, cells were quenched by putting them on ice 
and by the addition of 1 mL ice‐cold PBS. Cells were centri-
fuged for 5 minutes at 1000 g at 4°C and washed once with 
ice cold PBS. Cells were fixed and fluorescence quantified as 
described above.
To quantify the impact of suramin on the uptake of 
transferrin and LDL, cells were washed once with IMDM 
and eluted in IMDM without BSA to a concentration of 
2  ×  106  cells/mL. The experiment was performed without 
BSA, since otherwise the majority of suramin would bind to 
BSA. Cells were pre‐incubated for 15 minutes (transferrin) or 
for one hour (LDL) at 37°C. Suramin was added to concen-
trations between 0 and 1000 µmol/L and subsequently trans-
ferrin or LDL were added to concentrations of 5 or 10 µg/mL, 
respectively. Cells were incubated for 10 minutes (transfer-
rin) or for 20 minutes (LDL) at 37°C, quenched, washed, and 
fixed as described above.
For the quantification of transferrin and LDL binding to 
the cell surface, cells were washed with IMDM and eluted 
in IMDM to a concentration of 1 × 107 cells/mL. Cells were 
pre‐incubated for 15  minutes (transferrin) or for one hour 
(LDL) at 37°C and subsequently chilled on ice for 15 min-
utes. Either suramin or cold PBS was added and subsequently 
transferrin or LDL were added to a concentration of 800 or 
100 µg/mL, respectively. Cells were incubated for 10 minutes 
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on ice, subsequently washed twice with ice‐cold PBS and 
fixed as described above.
2.10 | Concanavalin A uptake and binding
Trypanosomes in the logarithmic growth phase were cen-
trifuged at 1000 g for 5 minutes, the cell pellet was eluted 
in IMDM with 1% bovine serum albumin (BSA) to a con-
centration of 2 × 106 cells/mL. 498 μL of eluted parasites 
were put in 1.5 ml Eppendorf tubes and pre‐incubated at 
37°C for 15 minutes. At the respective time points FITC 
conjugated Concanavalin A (C7642 Sigma, now Merck) 
was added to a concentration of 5  µg/mL. After incuba-
tion at 37°C cells were quenched on ice by the addition 
of ice‐cold PBS. Subsequently cells were centrifuged for 
5  minutes at 1000  g at 4°C and washed once with PBS. 
Cells were eluted in 250 µL PBS and fixed by the addition 
of 250 µL 10% formalin.
For the quantification of surface bound ConA, cells were 
centrifuged and eluted in IMDM with 1% BSA to a concen-
tration of 2 × 106 cells/mL. These were pre‐incubated on ice 
for 15 minutes and subsequently the ConA was added to con-
centrations of 0, 5, 20, and 50 µg/mL. After incubation on 
ice for 10 minutes, ice‐cold PBS was added, the cells centri-
fuged at 4°C (5 minutes, 1000 g) and subsequently washed 
one more time with ice‐cold PBS, eluted in 250 µL PBS, and 
fixed by the addition of 250 µL 10% formalin.
Fluorescent intensities of the cells were measured as de-
scribed above but using the FL1 filter. Fluorescence values 
were defined as the geometrical mean fluorescence of >9000 
events.
3 |  RESULTS
3.1 | Expression of VSGSur renders T. b. 
brucei resistant to suramin
To test the hypothesis that the expression of VSGSur is suffi-
cient to cause suramin resistance in T. brucei, we introduced 
the VSGSur gene into the active VSG expression site of T. b. 
brucei 2T1, a well‐established T. b. brucei bloodstream‐form 
laboratory line.12 2T1 cells naturally express VSG221,17 also 
called MITat1.2 (GenBank: X56762.1). To replace VSG221 
with VSGSur we made a construct (Figure 1A) which con-
tained the coding sequence of VSGSur together with a blas-
ticidine resistance gene, framed by the sequences of the 
5’  and 3’ regions of VSG221. Four transfected clones were 
recovered, all of which showed no expression of VSG221 
and expressed VSGSur at the same level as the parental line 
expressed VSG221 (determined by qPCR using telomerase 
reverse transcriptase (TERT) as a reference; Figure 1B). 
Two of the VSGSur expressing transfectants (2T1_sur1 and 
2T1_sur4) were chosen for further analysis. Proliferation was 
essentially indistinguishable from the parent cell line when 
cultivated in standard medium without blasticidine (Figure 
1C). The 50% inhibitory concentration (IC50) for suramin 
increased from 12 nmol/L in the VSG221 expressing parent 
to 700  nmol/L in the two VSGSur expressing transfectants 
(P = 0.0036, One‐Way ANOVA; Figure 1D). No alterations 
of drug sensitivities were observed for melarsoprol or pen-
tamidine, excluding a non‐specific drug resistance mecha-
nism. However, the VSGSur expressing cells showed weak 
cross resistance to trypan blue, with an elevation of the IC50 
from 13 µmol/L in the VSG221 expressing parent to 19 and 
21  µmol/L in the VSGSur expressing transfectants, but this 
was statistically non‐significant.
3.2 | VSGSur expressing cells show a reduced 
uptake of trypan blue
We exploited the fact that trypan blue becomes fluorescent 
when bound to proteins18,19 to investigate drug uptake by T. 
b. brucei 2T1. Cells were incubated with different concentra-
tions of trypan blue at 37°C and subsequently the fluorescence 
of cell‐associated trypan blue quantified by flow cytometry. 
In the cell size versus fluorescence scatters, gates were set to 
exclude dead cells, which give a much stronger signal than 
live cells.19 VSGSur‐expressors showed a 30%‐50% reduction 
in fluorescence when compared with their VSG221 expressing 
parent (Figure 2). This is consistent with the small increase in 
the IC50 towards this compound.
3.3 | VSGSur‐mediated suramin resistance 
is not linked to ISG75
Since some suramin resistance can be caused by ISG75 deple-
tion,6 we investigated a possible effect of VSGSur on ISG75 
turnover. Therefore, cells were incubated with cycloheximide 
to block protein synthesis, and the steady‐state ISG75 levels 
were determined after 0, 2, 4, and 6 hours by Western blotting. 
The ISG75 half‐life was around 3 hours in both the VSG221 
expressing and the VSGSur expressing trypanosomes (Figure 
3A). We further investigated the effect of ISG75 depletion in 
VSGSur‐expressors (2T1_sur1) and parental cells (2T1_wt) by 
introduction of a pRPA‐based, tetracycline‐inducible RNAi 
knock‐down construct. Induction of RNAi for 72 hours led to 
a 75%‐85% reduction in ISG75 mRNA levels in 5 (2T1_wt_c1 
and c3; 2T1_sur1_c1 to c3) of 6 clones as determined by qPCR 
(Figure 3B). Growth was slightly faster under knock‐down of 
ISG75 with an average population doubling time of 6.9 hours 
in the presence of tetracycline compared to 7.2 hours without 
tetracycline (P‐value = .003, paired t‐test including all clones, 
Figure 3C). Suramin sensitivity decreased in all the tested 
clones upon down‐regulation of ISG75 (Figure 3D). The pres-
ence of ISG75‐dependent suramin uptake also in the VSGSur‐
expressors indicates that this is not the pathway affected by 
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VSGSur. Moreover, the effect of ISG75 silencing on suramin 
sensitivity was clearly stronger (P = .009, Welch Two Sample 
t‐test) in the VSGSur‐expressors: the IC50 of suramin upon 
ISG75 knock‐down increased 2.2‐ and 3.8‐fold in parental 2T1 
cells, and 7.9‐, 8.1‐, and 6.7‐fold in VSGSur‐expressors (Figure 
3D). This is in agreement with the above hypothesis, that a 
pathway distinct from ISG75 is affected and hence, ISG75 
confers a larger proportion of suramin uptake in the VSGSur 
expressing trypanosomes.
3.4 | Effects of serum proteins on suramin 
susceptibility
Having excluded defects toward ISG75 turnover as a rea-
son for the decreased suramin sensitivity of VSGSur express-
ing cells, we tested for the involvement of serum proteins 
in VSGSur‐mediated suramin resistance. This had to be per-
formed with wash‐out assays since the trypanosomes can-
not be cultivated without serum proteins over long periods. 
F I G U R E  1  Introduction of VSGSur into the active bloodstream expression site renders 2T1 cells suramin resistant. A, Schematic illustration 
of VSG221 within the active bloodstream expression site of 2T1 cells before transfection and of the construct used for the in situ replacement of 
VSG221 with VSGSur. The construct is framed with the 5′ region of VSG221 with adjacent sequence on one side and the 3′ region of VSG221on the 
other side; it contains a blasticidine resistance gene (BSD), an αβ tubulin splice site (αβ tub), and the coding sequence (cds) of VSGSur. Triangles 
indicate restriction‐sites. B, Expression of VSGSur and VSG221 as determined by qPCR in the parent 2T1 strain (2T1_wt) and in four transfected 
clones (2T1_sur1‐4). Values shown are derived from technical duplicates; they represent expression levels normalized to the housekeeping gene 
TERT. The transfected clones show a high expression level of VSGSur, comparable to the expression level of VSG221 in the 2T1 parent cells. C, 
Cumulative cell number as measured over four days, error bars represent standard deviations (n = 3). D, Dose‐growth curves for suramin show an 
58‐fold decrease in suramin sensitivity after introduction of VSGSur (n = 3)
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F I G U R E  2  Trypan blue uptake. 
The trypan blue uptake of VSGSur and 
VSG221 expressing cells as determined by 
FACS after incubation for 2 h at 37°C. 
Error bars represent standard deviations of 
three independent experiments (*P < .05; 
**P < .01, paired t test)
F I G U R E  3  ISG75 expression and effect on suramin sensitivity (blue: parental, VSG221 expressing cells; red: VSGSur expressing cells). A, 
ISG75 turnover as determined by western blot after inhibition of translation for different time spans. Plotted data points represent mean amounts 
of protein from two independent experiments, for each experiment two technical replicates (western blots) were made. B, Reduction in ISG75 
expression levels upon RNAi knockdown. Gene expression levels are normalized to the housekeeping gene TERT, values shown are derived from 
technical duplicates. C, Cumulative growth curves of VSGSur and VSG221 expressing cells ± ISG75 knockdown. Values shown are the averaged 
growth curves for each group, including two biological replicates from each clone (2T1_wt_c1 and c3 for the VSG221‐expressor and 2T1_sur_c1, 
c2, and c3 for the VSGSur‐expressor). The data points represent mean cell numbers plotted with the position_dodge function in R to allow visual 
distinction between the groups. Error bars represent standard deviation. D, 50% inhibitory concentrations for suramin of VSGSur and VSG221 
expressing cells ± ISG75 knockdown. ∆ represents the factor of increase upon ISG75 knockdown
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Parental, VSG221 expressing 2T1 cells and VSGSur‐expressors 
were incubated for 4 hours with suramin in HMI‐9 medium 
without serum proteins, in HMI‐9 supplemented with albu-
min, with LDL or with serum, respectively, washed, and 
incubated in standard growth medium (without suramin) for 
3 days. As expected, the IC50 in these assays (Figure 4) were 
higher than in the standard 72 hours assay, since suramin was 
only present for the first 4  hours. Nevertheless, cells incu-
bated in medium without any serum proteins were highly 
sensitive to suramin: they showed a decrease in IC50 of 98% 
for VSG221 and of 95% for VSGSur‐expressing cells when 
compared with the IC50 of cells incubated in medium with 
serum. This demonstrates that free suramin is taken up by 
trypanosomes. The addition of bovine serum albumin (BSA) 
counteracted suramin toxicity, indicating that suramin is se-
questered by binding to albumin, which is in agreement with 
previous findings.5 The same effect can also explain why the 
trypanosomes were less suramin sensitive in the presence of 
serum than without serum. The addition of LDL further in-
creased suramin susceptibility of serum‐free cultures (50% 
decrease in IC50; Figure 4). However, this effect was only 
observed in parental, VSG221 expressing cells but not in the 
VSGSur expressing cells (P‐value = .008, paired t test). These 
data suggest that VSGSur expression abolished LDL‐mediated 
uptake of suramin.
3.5 | The effect of VSGSur and suramin on 
LDL uptake
To measure uptake of LDL, T. b. brucei 2T1 cells were in-
cubated for different times with fluorescently labeled LDL 
at 37°C to allow endocytosis, and the internalized LDL 
was quantified using FACS. No plateau was reached within 
120  minutes incubation time, neither for VSG221 nor for 
VSGSur expressing cells (Figure 5A). LDL uptake was highly 
reduced in VSGSur expressing cells with an 80%‐90% lower 
fluorescence than VSG221‐expressors throughout the 5 to 
120  minutes period (Figure 5A). The presence of suramin 
led to reduction in LDL uptake in wild‐type cells but not in 
VSGSur‐expressors (Figure 5B). To differentiate whether the 
reduced LDL uptake is mediated through a reduced bind-
ing or endocytosis, we looked at the binding of LDL to the 
cell surface. LDL binding at 4°C was around 30% reduced 
in VSGSur compared to VSG221 expressing cells (overall P‐
value = .0003, paired t‐test). Thus, the highly reduced LDL 
uptake cannot be explained by a reduction in the binding 
alone and a reduced endocytosis seems to play a major role. 
No effect on binding was observed in the presence of suramin 
(Figure 5C).
3.6 | The effect of VSGSur and suramin on 
transferrin uptake
We investigated uptake of transferrin as an additional sub-
strate that is imported by receptor‐mediated endocytosis.20,21 
Again, trypanosomes were incubated for different periods 
with fluorescently labeled transferrin at 37°C and analyzed 
by FACS. In VSG221 expressing 2T1 cells transferrin was 
quickly internalized, reaching a plateau of more than four 
times background fluorescence after ten minutes (Figure 6A). 
In contrast, VSGSur expressing 2T1 cells incubated with la-
beled transferrin only showed a slight increase in fluorescence 
F I G U R E  4  50% inhibitory 
concentrations in the presence of different 
serum proteins. Parasites were incubated 
either in standard growth medium with 15% 
inactivated horse serum (HMI‐9), in HMI‐
medium without any serum (no serum), in 
HMI‐medium without serum supplemented 
with albumin (BSA), or in HMI‐medium 
without serum supplemented with LDL 
(LDL). Values that differed significantly 
(P < .05, Tukey's multiple comparison 
test on logarithmic data) are labeled 
with different letters (a‐g) (independent 
biological replicates: n = 3 for “HMI‐9” and 
“BSA”; n = 4 for “no serum,” and “LDL”; 
each biological replicate consisted of two 
technical replicates)
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F I G U R E  5  Uptake and binding of 
fluorescently labeled low‐density lipoprotein 
and the effect of suramin. A, Uptake of 
low‐density lipoprotein over a period of 
2 h, error bars represent standard deviations 
(*P < .05; **P < .01; n = 3 for timepoint 
120 min; n = 4 for timepoints 0‐60 min; 
paired t test). B, Impact of suramin on the 
uptake of LDL during 20 min of incubation, 
asterisk represent significant p‐values if 
fluorescence of VSG221 expressing cells 
under incubation with suramin is compared 
to the fluorescence of VSG221 expressing 
cells under incubation without suramin 
(*P < .05; **P < .01; ***P < .001; n = 3, 
pairwise t‐test with Bonferroni correction), 
error bars represent standard deviations. 
Dotted lines represent baseline, which 
was defined as fluorescence of cells which 
were incubated with the same amount of 
LDL but on ice to inhibit endocytosis. C, 
Binding of LDL to the cell surface. Dotted 
lines represent background fluorescence 
of VSG221 expressing (blue) and VSGSur 
expressing (red) cells incubated without 
fluorescently labeled LDL. Error bars 
represent standard deviations of three 
measurements (two for 10 mmol/L suramin)
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F I G U R E  6  Uptake and binding of 
fluorescently labeled transferrin and the 
effect of suramin. A, Transferrin uptake of 
VSGSur and VSG221 expressing cells at 37°C 
over time. Error bars represent standard 
deviation of four independent experiments 
(*P < .05; **P < .01, paired t test). B, 
Influence of suramin on transferrin uptake. 
Data of three independent experiments 
are shown, error bars represent standard 
deviations. Dotted lines represent baseline, 
which was defined as fluorescence of 
cells which were incubated with the same 
amount of transferrin but on ice to inhibit 
endocytosis. C, Transferrin binding to the 
cell surface with and without suramin as 
determined after incubation of cells on 
ice. Dotted lines represent background 
fluorescence of VSG221 expressing (blue) 
and VSGSur expressing (red) cells incubated 
without fluorescently labeled transferrin. 
Error bars represent standard deviations of 
three measurements (two for 10 mmol/L 
suramin)
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to 1.5 times background level (Figure 6A), which corre-
sponds to an 80% lower fluorescence than observed in pa-
rental cells. Since transferrin uptake had been described to 
be reduced in the presence of suramin in HeLa cells,22 we 
investigated the effect of suramin on transferrin uptake in T. 
brucei. Cells were incubated with fluorescently labeled trans-
ferrin in different concentrations of suramin for 10 minutes 
(the incubation time was kept short to limit the toxic effects 
of suramin). At concentrations below 300 µmol/L, suramin 
had no effect on transferrin uptake; only at very high suramin 
concentrations, reduced amounts of intracellular transferrin 
were measured in VSG221 expressing cells (Figure 6B, P‐
values of .04 and .006 for concentrations of 300 and 1000, 
respectively, pairwise t test with Benjamini Hochberg correc-
tion). To differentiate whether the reduced internalization of 
transferrin in VSGSur expressing cells was caused by reduced 
binding or reduced endocytosis, we quantified surface bind-
ing of transferrin to trypanosomes by incubating the cells on 
ice. The fluorescence of VSGSur expressing cells incubated 
without suramin was around 40% lower than the fluorescence 
of the VSG221 expressing cells (Figure 6). Thus again, the 
highly reduced transferrin uptake cannot be attributed to re-
duced binding. Upon addition of suramin at 1 mmol/L and 
10 mmol/L, the difference between VSG221 and VSGSur‐ex-
pressors became smaller (Figure 6C). However, at such high 
suramin concentrations we cannot exclude an ionic effect. 
The overall p‐value of the difference between VSG221 and 
VSGSur‐expressors was 0.03.
3.7 | The effect of VSGSur on VSG 
endocytosis
Variant surface glycoproteins are endocytosed at a very 
high rate with a turnover equivalent to the whole surface 
coat within 12 minutes.23 To test whether VSGSur expression 
has a general impact on endocytosis, we investigated endo-
cytosis of VSGSur and VSG221. Concanavalin A (ConA) is a 
lectin that binds to glycosylated surface proteins, in case of 
trypanosomes mainly to VSG.24 It is endocytosed together 
with the VSG and can therefore be used to measure VSG 
endocytosis rates. Cells were incubated for time periods of 
0 to 60 minutes at 37°C with 5 µg/mL fluorescently labeled 
ConA. Subsequently cells were fixed, and the fluorescence 
of cell‐associated ConA was measured by flow cytometry. 
Up to an incubation period of 20 minutes fluorescence levels 
were in the same range or even higher for VSGSur than for 
VSG221‐expressors. Thereafter VSGSur‐expressors showed a 
slightly lower fluorescence than VSG221‐expressors (Figure 
7A). Since ConA does not bind equally well to all VSGs24 
we examined the ConA‐binding capacity of the two cell 
lines. The cells were incubated with different concentrations 
of ConA on ice to prevent endocytosis, and surface bound 
ConA was quantified by flow cytometry. VSGSur expressing 
cells showed a 22%‐34% higher fluorescence than VSG221‐
expressors (P‐value = .0097, paired t‐test, Figure 7B). Taken 
together, the facts that VSGSur‐expressors showed similar 
levels of internalized ConA as VSG221‐expressors at 37°C 
but more surface bound ConA at 4°C, indicate that endocy-
tosis of VSG may be slightly reduced in VSGSur expressing 
cells. However, we observed no enlargement of the flagellar 
pocket, which is a hallmark for blocked endocytosis.
3.8 | The effect of VSGSur on sensitivity to 
human serum
Most trypanosome species other than T. b. rhodesiense and T. 
b. gambiense are lysed by the two trypanolytic factors (TLF1 
and TLF2) present in human serum. TLF1, a high‐density 
lipoprotein complex, and TLF2, a protein complex, both 
contain apolipoprotein L1,25 which mediates trypanolysis.26 
TLF1 is much more active than TLF2 and kills T. b. bru-
cei at very low concentrations in the absence of competing 
haptoprotein.27 TLF1 binds to the haptoglobin‐hemoglobin 
receptor (TbHpHbR) in the flagellar pocket and is subse-
quently endocytosed.28 To test whether the endocytosis of 
the TbHpHbR is affected by VSGSur expression, sensitivity 
to human serum was tested. However, bloodstream‐form 
T. b. brucei 2T1 expressing VSGSur or VSG221 were equally 
sensitive (Figure 8). This demonstrates that endocytosis of 
the trypanolytic factor of human serum, and the downstream 
mechanisms of cell lysis, are not affected by VSGSur.
4 |  DISCUSSION
We have originally identified VSGSur as the VSG expressed 
in bloodstream‐form T. brucei spp. that had been selected in 
vitro for resistance to suramin.11 The resistant cells had IC50 
values to suramin of around 1.2 µmol/L, which was almost 
100‐fold above the IC50 of the parental cells but still below 
the suramin plasma levels of 70 µmol/L in treated patients.29 
Thus the expression of VSGSur is unlikely to cause suramin 
treatment failure in patients. Nevertheless, it is intriguing 
how a particular VSG can be linked to drug susceptibility.
Here we show that transgenic expression of VSGSur is 
sufficient to cause suramin resistance in T. b. brucei, which 
is otherwise highly sensitive to the drug. Based on the re-
duced uptake of trypan blue by the cells that express VSGSur, 
our working hypothesis is that suramin resistance is medi-
ated by a reduced drug uptake. Trypanosomes take up sur-
amin through receptor‐mediated endocytosis.4,5 Endocytosis 
in trypanosomes takes place at the flagellar pocket and the 
most abundantly endocytosed protein is VSG itself. VSGs are 
endocytosed into Rab5a endosomes30 at a very high rate.23 
Subsequently the VSG is recycled back to the trypanosome 
surface by exocytosis via Rab11 exocytic carriers.31
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F I G U R E  7  Concanavalin A 
uptake and binding in VSGSur and VSG221 
expressing cells. A, Fluorescence of cells 
incubated with 5 µg/mL labeled ConA 
at 37°C, time point zero represents cells 
that were kept on ice before the addition 
of ConA in order to allow binding but 
not uptake. Error bars represent standard 
deviations of five (for timepoint 60 
only four) independent experiments. 
B, Fluorescence of surface bound 
ConA of cells incubated with different 
ConA concentrations at 4°C to prevent 
endocytosis. Error bars represent standard 
deviation of four independent experiments
F I G U R E  8  Sensitivity to normal 
human serum
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Concanavalin A, a lectin which binds to VSG, can be used 
as a marker to track VSG internalization.32 We did not observe 
distinct alterations of ConA endocytosis in VSGSur expressing 
trypanosomes, neither by flow cytometry nor by fluorescence 
microscopy (not shown) and conclude that if there is an effect 
on VSG internalization at all, it is only marginal. Transferrin 
and low‐density lipoprotein (LDL) are important nutrients for 
African trypanosomes.33,34 Transferrin binds to the transferrin 
receptor, which is a heterodimer of ESAG6 and ESAG7, and is 
subsequently endocytosed in Rab5a endosomes similar to the 
VSGs.30 Once the ligand is removed, transferrin receptors are 
recycled to the cell membrane. Similar to VSG, this happens at 
a very high rate with a turnover of only 11 minutes.35 LDL is 
imported via receptor‐mediated endocytosis as well. The LDL 
receptor is supposedly located at the flagellar pocket and on the 
flagellar membrane,36 but it has not been identified. As deter-
mined by flow cytometry, the VSGSur‐expressors showed highly 
reduced intracellular levels of fluorescently labeled transferrin 
and fluorescently labeled LDL after incubation at 37°C. This 
suggests that VSGSur expression impairs endocytosis of the 
LDL receptor and the transferrin receptor. However, the expres-
sion of VSGSur did not alter sensitivity to human serum, indi-
cating that endocytosis of the TbHpHb receptor is not affected. 
The HpHb receptor is a glycosylphosphatidylinositol (GPI) 
anchored, glycosylated surface protein located at the flagellar 
pocket.28 Taken together, VSGSur‐expressors showed a normal 
growth and no enlarged flagellar pockets, thus we assume that 
VSGSur has no effect on bulk endocytosis. Receptor‐mediated 
endocytosis is affected by VSGSur, but only specific pathways. 
While endocytosis of transferrin is highly reduced, endocytosis 
of the VSG may be moderately reduced, and endocytosis of the 
HpHb receptor unaffected by VSGSur expression. Additionally, 
and most importantly for suramin susceptibility, endocytosis of 
the elusive LDL receptor is highly reduced.
Suramin inhibited uptake of LDL by VSG221 expressing 
cells, in agreement with published results,5 but not in VSGSur 
expressing cells. Short‐term suramin wash‐out experiments 
in serum‐free medium indicated that suramin uptake is low-
est in the presence of albumin and intermediate in the pres-
ence of serum, which confirms the literature.5 We further 
show for the first time that suramin is also taken up in the 
absence of serum. The addition of LDL appeared to increase 
suramin uptake in VSG221 expressing cells, which is in accor-
dance with the literature,5 but not in VSGSur‐expressors. On 
the other hand, knockdown of ISG75 had a stronger effect 
on suramin sensitivity in VSGSur‐expressors than in VSG221 
expressing cells.
Suramin remains an enigmatic molecule with polyphar-
macology and multiple potential uses. The effects of suramin 
on vesicular trafficking are likely to be complex, since sura-
min can interfere with vesicular transport and is imported via 
receptor‐mediated endocytosis itself.4,5,7 Our findings sup-
port a model of two independent pathways for endocytosis 
of suramin by trypanosomes: via the invariant surface glyco-
protein ISG75 that directly binds suramin, and via the LDL 
receptor, a protein of unknown nature that binds suramin 
complexed to LDL. While the former is still active in cells 
expressing VSGSur, the latter is strongly impaired, causing 
suramin resistance in T. brucei.
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